Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice

Background. Imatinib, the first BCR/ABL kinase inhibitor, has drastically changed the chronic myeloid leukemia (CML) scenario improving the rate of responses and long-term outcome. The aim of our analysis was to assess, after a median follow-up of 10.2 years (range 5.8-14.8), the long-term efficacy and safety of imatinib treatment in a monocentric cohort of CML patients treated outside of clinical trials. Methods. We retrospectively analyzed a series of 458 CML patients treated with imatinib frontline or after interferon (IFN) failure at a single center between 2000 and 2016. Long-term analysis included overall survival (OS), progression-free survival (PFS), event-free survival (EFS), response to treatment and adverse events. Results. The median age was 55.1 years (range 18.8-91.2). Seventy-one % of patients received imatinib frontline and 29% after IFN failure. Median time of prior IFN treatment was 5.6 years (range 2.4-8.9); the 10-year OS of patients treated with imatinib after IFN and with imatinib frontline was 75.3% (CI 95%: 66.9-81.9) and 77.8% (CI 95%: 72.2-82.5) (p=0.468), respectively. The 10-year-OS of the whole cohort was 77.1% (CI 95%: 73.1-81.5); the 10-year probability of dying due to CML and of other causes was 7.8% (CI 95%: 5.1-10.3) and 16% (CI 95%: 11.5-18.8), respectively (Figure 1). When patients were stratified into 4 groups according to age (18-35, >35- 50- 65 years), no difference was found in the 10-year OS considering only the CML-related deaths (p=0.472), whereas a difference was observed when all other causes of death were considered (p Conclusions. A 10-year real-life follow-up of CML patients demonstrates that imatinib maintains efficacy over time and is associated with a low rate of CV events and second neoplasias. Disclosures Rizzo:Sapienza University, Rome: Other: Resident in Hematology. Foa:GILEAD: Speakers Bureau; INCYTE: Other: ADVISORY BOARD; AMGEN: Other: ADVISORY BOARD; ABBVIE: Other: ADVISORY BOARD, Speakers Bureau; CELTRION: Other: ADVISORY BOARD; NOVARTIS: Speakers Bureau; JANSSEN: Other: ADVISORY BOARD, Speakers Bureau; CELGENE: Other: ADVISORY BOARD, Speakers Bureau; ROCHE: Other: ADVISORY BOARD, Speakers Bureau. Breccia:Novartis: Honoraria; BMS: Honoraria; Incyte: Honoraria; Pfizer: Honoraria.